标题
Development of immuno-oncology drugs — from CTLA4 to PD1 to the next generations
作者
关键词
-
出版物
NATURE REVIEWS DRUG DISCOVERY
Volume 15, Issue 4, Pages 235-247
出版商
Springer Nature
发表日期
2016-03-11
DOI
10.1038/nrd.2015.35
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Phase III, open-label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma
- (2017) A. Ribas et al. JOURNAL OF CLINICAL ONCOLOGY
- Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
- (2015) Suzanne L. Topalian et al. CANCER CELL
- Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
- (2015) Padmanee Sharma et al. CELL
- Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25
- (2015) Dalil Hannani et al. CELL RESEARCH
- CCR 20th Anniversary Commentary: Immune-Related Response Criteria--Capturing Clinical Activity in Immuno-Oncology
- (2015) A. Hoos et al. CLINICAL CANCER RESEARCH
- The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4
- (2015) L. Liu et al. CLINICAL CANCER RESEARCH
- The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?
- (2015) Daniel Sanghoon Shin et al. CURRENT OPINION IN IMMUNOLOGY
- Bispecific antibodies
- (2015) Roland E. Kontermann et al. DRUG DISCOVERY TODAY
- Complete Cytologic Remission of V600E BRAF-Mutant Melanoma–Associated Leptomeningeal Carcinomatosis Upon Treatment With Dabrafenib
- (2015) Sofie Wilgenhof et al. JOURNAL OF CLINICAL ONCOLOGY
- Five-Year Survival Rates for Treatment-Naive Patients With Advanced Melanoma Who Received Ipilimumab Plus Dacarbazine in a Phase III Trial
- (2015) Michele Maio et al. JOURNAL OF CLINICAL ONCOLOGY
- Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
- (2015) Robert H.I. Andtbacka et al. JOURNAL OF CLINICAL ONCOLOGY
- Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
- (2015) Dirk Schadendorf et al. JOURNAL OF CLINICAL ONCOLOGY
- Milestone Survival: A Potential Intermediate Endpoint for Immune Checkpoint Inhibitors
- (2015) Tai-Tsang Chen JNCI-Journal of the National Cancer Institute
- Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial
- (2015) Ana Maria Henao-Restrepo et al. LANCET
- Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
- (2015) Jeffrey S Weber et al. LANCET ONCOLOGY
- Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
- (2015) Alexander M M Eggermont et al. LANCET ONCOLOGY
- Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
- (2015) Max S Topp et al. LANCET ONCOLOGY
- NY-ESO-1–specific TCR–engineered T cells mediate sustained antigen-specific antitumor effects in myeloma
- (2015) Aaron P Rapoport et al. NATURE MEDICINE
- Guidelines for the automated evaluation of Elispot assays
- (2015) Sylvia Janetzki et al. Nature Protocols
- Big opportunities for small molecules in immuno-oncology
- (2015) Jerry L. Adams et al. NATURE REVIEWS DRUG DISCOVERY
- Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
- (2015) Stephen M. Ansell et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Severe gastrointestinal toxicity with administration of trametinib in combination with dabrafenib and ipilimumab
- (2015) David R. Minor et al. Pigment Cell & Melanoma Research
- A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells
- (2015) B. M. Carreno et al. SCIENCE
- Immune Checkpoint Inhibitors in Melanoma Provide the Cornerstones for Curative Therapies
- (2015) Alexander M.M. Eggermont et al. SEMINARS IN ONCOLOGY
- Immunologic Checkpoints Blockade in Renal Cell, Prostate, and Urothelial Malignancies
- (2015) Sergio Bracarda et al. SEMINARS IN ONCOLOGY
- Milestone Survival: A Potential Intermediate Endpoint for Immune Checkpoint Inhibitors
- (2015) Tai-Tsang Chen JNCI-Journal of the National Cancer Institute
- NKG2D Receptor and Its Ligands in Host Defense
- (2015) L. L. Lanier Cancer Immunology Research
- Pembrolizumab: First Global Approval
- (2014) Raewyn M. Poole DRUGS
- Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies
- (2014) Saar Gill et al. IMMUNOLOGICAL REVIEWS
- Phase II Trial of the Anti-CD19 Bispecific T Cell–Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia
- (2014) Max S. Topp et al. JOURNAL OF CLINICAL ONCOLOGY
- Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial
- (2014) Eugene D Kwon et al. LANCET ONCOLOGY
- Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
- (2014) Matthew M. Gubin et al. NATURE
- A vaccine targeting mutant IDH1 induces antitumour immunity
- (2014) Theresa Schumacher et al. NATURE
- MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
- (2014) Thomas Powles et al. NATURE
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma
- (2014) Carsten Linnemann et al. NATURE MEDICINE
- Therapeutic vaccines for cancer: an overview of clinical trials
- (2014) Ignacio Melero et al. Nature Reviews Clinical Oncology
- Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
- (2014) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy
- (2014) D. Zamarin et al. Science Translational Medicine
- Tumor-Antigen–Binding Bispecific Antibodies for Cancer Treatment
- (2014) Ulrich H. Weidle et al. SEMINARS IN ONCOLOGY
- Combination of 4-1BB Agonist and PD-1 Antagonist Promotes Antitumor Effector/Memory CD8 T Cells in a Poorly Immunogenic Tumor Model
- (2014) S. Chen et al. Cancer Immunology Research
- Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma
- (2013) G. P. Linette et al. BLOOD
- Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme
- (2013) Anna Maria Di Giacomo et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- From the immune contexture to the Immunoscore: the role of prognostic and predictive immune markers in cancer
- (2013) Helen Angell et al. CURRENT OPINION IN IMMUNOLOGY
- Oncology Meets Immunology: The Cancer-Immunity Cycle
- (2013) Daniel S. Chen et al. IMMUNITY
- Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma
- (2013) Antoni Ribas et al. JOURNAL OF CLINICAL ONCOLOGY
- TLR agonists: our best frenemy in cancer immunotherapy
- (2013) Sabina Kaczanowska et al. JOURNAL OF LEUKOCYTE BIOLOGY
- Combined TIM-3 blockade and CD137 activation affords the long-term protection in a murine model of ovarian cancer
- (2013) Zhiqiang Guo et al. Journal of Translational Medicine
- Signatures of mutational processes in human cancer
- (2013) Ludmil B. Alexandrov et al. NATURE
- The regulatory landscape for actively personalized cancer immunotherapies
- (2013) Cedrik M Britten et al. NATURE BIOTECHNOLOGY
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
- (2013) Omid Hamid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Designing Tomorrow's Vaccines
- (2013) Gary J. Nabel NEW ENGLAND JOURNAL OF MEDICINE
- Hepatotoxicity with Combination of Vemurafenib and Ipilimumab
- (2013) Antoni Ribas et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab plus Ipilimumab in Advanced Melanoma
- (2013) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ipilimumab and Its Toxicities: A Multidisciplinary Approach
- (2013) L. A. Fecher et al. ONCOLOGIST
- Cancer Immunotherapy
- (2013) J. Couzin-Frankel SCIENCE
- Increased Frequency of ICOS+ CD4 T Cells as a Pharmacodynamic Biomarker for Anti-CTLA-4 Therapy
- (2013) D. Ng Tang et al. Cancer Immunology Research
- Evolution of end points for cancer immunotherapy trials
- (2012) A. Hoos ANNALS OF ONCOLOGY
- Immunogenic Cell Death in Cancer Therapy
- (2012) Guido Kroemer et al. Annual Review of Immunology
- Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody
- (2012) E. J. Lipson et al. CLINICAL CANCER RESEARCH
- T Cell Assays and MIATA: The Essential Minimum for Maximum Impact
- (2012) C.M. Britten et al. IMMUNITY
- The Chemokine Superfamily Revisited
- (2012) Albert Zlotnik et al. IMMUNITY
- Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study
- (2012) Thomas J. Lynch et al. JOURNAL OF CLINICAL ONCOLOGY
- Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
- (2012) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- The immuno-oncology framework
- (2012) Axel Hoos et al. OncoImmunology
- Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape
- (2011) S.-R. Woo et al. CANCER RESEARCH
- Histopathologic-Based Prognostic Factors of Colorectal Cancers Are Associated With the State of the Local Immune Reaction
- (2011) Bernhard Mlecnik et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeted Therapy With the T-Cell–Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival
- (2011) Max S. Topp et al. JOURNAL OF CLINICAL ONCOLOGY
- Cancer immunotherapy comes of age
- (2011) Ira Mellman et al. NATURE
- A methodological framework to enhance the clinical success of cancer immunotherapy
- (2011) Axel Hoos et al. NATURE BIOTECHNOLOGY
- Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia
- (2011) David L. Porter et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- (2011) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
- (2011) R. D. Schreiber et al. SCIENCE
- Harmonization of Immune Biomarker Assays for Clinical Studies
- (2011) S. H. van der Burg et al. Science Translational Medicine
- Cytokines in Cancer Immunotherapy
- (2011) Sylvia Lee et al. Cancers
- Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study
- (2010) S. J. O'Day et al. ANNALS OF ONCOLOGY
- Improved Endpoints for Cancer Immunotherapy Trials
- (2010) A. Hoos et al. JNCI-Journal of the National Cancer Institute
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Development of Ipilimumab: Contribution to a New Paradigm for Cancer Immunotherapy
- (2010) Axel Hoos et al. SEMINARS IN ONCOLOGY
- Do We Need a Different Set of Response Assessment Criteria for Tumor Immunotherapy?
- (2009) A. Ribas et al. CLINICAL CANCER RESEARCH
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- (2009) J. D. Wolchok et al. CLINICAL CANCER RESEARCH
- Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
- (2009) Jedd D Wolchok et al. LANCET ONCOLOGY
- The cancer vaccine roller coaster
- (2009) Bruce Goldman et al. NATURE BIOTECHNOLOGY
- PD-1 and Its Ligands in Tolerance and Immunity
- (2008) Mary E. Keir et al. Annual Review of Immunology
- Phase I/II Study of Ipilimumab for Patients With Metastatic Melanoma
- (2008) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients
- (2008) F. S. Hodi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search